Journal article
The induction and maintenance of transplant tolerance engages both regulatory and anergic CD4+ T cells.
- Abstract:
- Therapeutic tolerance to self-antigens or foreign antigens is thought to depend on constant vigilance by Foxp3+ regulatory T cells (Tregs). Previous work using a pancreatic islet allograft model and a short pulse of CD3 antibody therapy has shown that CD8+ T cells become anergic and use TGFβ and coinhibitory signaling as their contribution to the tolerance process. Here, we examine the role of CD4+ T cells in tolerization by CD3 antibodies. We show that both Foxp3+ Tregs and CD4+ T cell anergy play a role in the induction of tolerance and its maintenance. Foxp3+ Tregs resisted CD3 antibody-mediated depletion, unlike intragraft Th1 CD4+ lymphocytes coexpressing granzyme B and Tbx21, which were selectively eliminated. Tregs were mandatory for induction of tolerance as their depletion at the time of CD3 antibody therapy or for a short time thereafter, by an antibody to CD25 (PC61), led to graft rejection. Early treatment with CTLA-4 antibody gave the same outcome. In contrast, neither PC61 nor anti-CTLA-4 given late, at day 100 posttransplant, reversed tolerance once established. Ablation of Foxp3 T cells after diphtheria toxin injection in tolerant Foxp3DTR recipient mice provided the same outcome. Alloreactive T cells had been rendered intrinsically unresponsive as total CD4+ or Treg-deprived CD4+ T cells from tolerant recipients were unable to mount donor-specific IFN-γ responses. In addition, intragraft Treg-deprived CD4+ T cells lacked proliferative capacities, expressed high levels of the inhibitory receptor PD-1, and exhibited a CD73hiFR4hi phenotype, thus reflecting a state of T cell anergy. We conclude that Tregs play a substantive and critical role in guiding the immune system toward tolerance of the allograft, when induced by CD3 antibody, but are less important for maintenance of the tolerant state, where T cell anergy appears sufficient.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.9MB, Terms of use)
-
- Publisher copy:
- 10.3389/fimmu.2017.00218
Authors
Dutch Kidney Foundation.
More from this funder
University Paris Descartes
More from this funder
Fondation Centaure
More from this funder
Fondation Day Solvay
More from this funder
Sixth Framework Programme
More from this funder
- Publisher:
- Frontiers Media
- Journal:
- Frontiers in Immunology More from this journal
- Volume:
- 8
- Pages:
- 218
- Publication date:
- 2017-03-01
- Acceptance date:
- 2017-02-15
- DOI:
- EISSN:
-
1664-3224
- Pmid:
-
28321218
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:686993
- UUID:
-
uuid:ecac5835-8e27-4394-addd-8d11848c882b
- Local pid:
-
pubs:686993
- Source identifiers:
-
686993
- Deposit date:
-
2017-09-07
- ARK identifier:
Terms of use
- Copyright holder:
- Waldmann et al
- Copyright date:
- 2017
- Notes:
- Copyright © 2017 Besançon, Baas, Goncalves, Valette, Waldmann, Chatenoud and You. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record